CFTR and cystic fibrosis: In recent times, the COVID-19 pandemic, including the subsequent rollout of an effective vaccination program, complemented by the impact of social distancing and personal hygiene measures on the spread of all respiratory viruses at different stages of the pandemic and the dramatic positive impact of CFTR modulator therapies for those now on these medications, have resulted in highly variable healthcare utilization and morbidity in CF patients.